TABLE III.
Sensitivity for Detection of Malignant Pheochromocytoma/Paraganglioma
| Reference | Patient-based sensitivity (lesion-based sensitivity in parentheses) | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Number of patientsa | MIBG | SRS | FDG | FDA | FDOPA | CT | MRI | |
| [114] | 64 | 92.4%b | ||||||
| [68] | 17 | 82%c | 88% | |||||
| [112] | 14 | 57%d | 87.5% | |||||
| [66] | 53 | 70.6%d | 88.9% | 91.4% | 100%e | 100%e | ||
| [73] | 9 | 75%b | 89% | 100% | ||||
| [62] | 30 SDHB | 80%c | 100% | 88% | ||||
| [54] | 28 | 84% (57%)d | 89%(74%) | 81%(76%) | 74%(45%)f | (100%)e | (100%)e | |
| [115] | 28 | 100% | ||||||
| [71] | 21 | (56%)d | (73%) | (45%) | ||||
| [72] | 12 | 75%d (38%) | 100% (98%) | |||||
a
Data for malignant PGL only, some studies included both benign and malignant PGL.
b
I-131 MIBG.
c
Either I-123 or I-131.
d
I-123 MIBG.
e
Studies used either CT or MRI.
f
This represents a mixed population, in SDHB the per lesion was sensitivity of FDOPA was 20% whereas in non-SDHB it was 93%.